Protocol Ledger

NCT07566156 · Phase III · RECRUITING

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Interventional Phase III clinical trial protocol NCT07566156 sponsored by Astellas Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-11 Enrollment: 390 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07566156
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)390 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07566156
Protocol FieldVerified Registry Value
NCT IdentifierNCT07566156
Consolidated Lead SponsorAstellas Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment390 participants (ESTIMATED)
Registered Start Date2026-05-11
WhyStopped ClassificationNot Stopped

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI